SaferWorldbyDesign Webinar: The NeuroDeRisk IL Profiler: DeRisking Chemical Structures for Neurotoxic Adverse Outcomes

Adverse effects of pharmaceuticals on the central or peripheral nervous  systems are poorly predicted by current preclinical studies. To address this,  the NeuroDeRisk IL Profiler was developed as one of the results of the  NeuroDeRisk Project [1,2]. It is an innovative software solution, that enables the identification of chemicals with potential risk for neurotoxic adverse events  covering seizures/convulsions, psychological/psychiatric effects, and  peripheral neuropathies. It provides the ability to profile and rank structures for  neuropharmacology and risk; support for med chem decisions, advancing  research on MIEs, multi-target neurotoxicity, and nomination of chemicals for  experimental studies. It strengthens the 3Rs approach (“Reduce, Refine,  Replace”) and increases productivity towards development of safer  pharmaceuticals. Early assessment of risk for neurotoxicity will benefit human  volunteers and patients through safer, preclinical candidates and  pharmaceutical drugs.  

Presenter: Sharon Bryant (Inte:Ligand Gmbh) 

Sharon Bryant, CEO at Inte:Ligand GmbH, has more than 30 years experience in computer aided molecular design, working extensively with pharmaceutical, cosmetic, and nutrition industries to provide robust in silico solutions to identify bioactive molecules, provide chemistry design/decision support and preclinical safety prediction models. She was previously at the NIEHS, National Toxicology program, USA, has authored more than 150 scientific publications and is Guest Professor at the University of Vienna, in the Master in Preclinical Drug Discovery program. 

[1] The NeuroDeRisk IL Profiler [https://docs.inteligand.com/ndr/il-profiler/]. [2]  The NeuroDeRisk Project. [https://neuroderisk.eu/].